Kazia files final prospectus, discloses new details on TNBC data and share count after $40M offering

Kazia Therapeutics Limited's public offering, priced August 28, 2026, is now detailed in a prospectus supplement that also discloses interim clinical data and updated capitalization figures not previously reported.

The company disclosed that in its ongoing trials evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with advanced metastatic TNBC, six of six evaluable patients treated with paxalisib-based regimens have demonstrated clinical benefit, with five of the six achieving an objective response for an 83% objective response rate, including one complete metabolic response, four partial responses, and one stable disease.¹ In the ongoing trial, zero paxalisib-related serious adverse events, zero suspected unexpected serious adverse reactions, and zero significant safety issues have been reported, though thirteen total SAEs were reported, all assessed as unrelated or unlikely related to paxalisib.¹ The company noted that its Phase 1b trial is not designed or powered to demonstrate statistical significance and investors should not place undue reliance on these preliminary results.¹

On share counts, Kazia disclosed it had 5,667,995,734 ordinary shares outstanding as of December 31, 2025, and has since issued 816,443,500 additional ordinary shares via multiple transactions, bringing the total to 6,484,439,234 ordinary shares outstanding as of August 26, 2026.¹ After the offering, the company expects 7,774,439,234 ordinary shares outstanding on an actual basis, before exercise of any warrants, and 9,928,178,234 ordinary shares outstanding on a fully as-adjusted basis assuming exercise in full of all Pre-Funded Warrants, Series A Warrants and Series B Warrants.¹

Warrant terms remain as previously reported: Series A Warrants carry a $17.825 exercise price and expire 30 days after the company announces at least 12 patients in the TNBC trial reach six-month median progression-free survival, or five years from issuance.¹ Series B Warrants carry a $19.375 exercise price tied to a similar milestone in the planned HR+/HER2- breast cancer evaluation.¹ Net proceeds are estimated at approximately $37 million after fees.¹